目的评价小剂量丝裂霉素膀胱内序列灌注预防浅表性膀胱癌术后复发的疗效及安全性。方法对1998年至2004年42例浅表性膀胱癌患者术后进行膀胱内灌注化疗,其中32例行经尿道膀胱肿瘤(TURBt)电切术,10例行膀胱部分切除术,所有入选病例均经病理证实为浅表性肿瘤,术后1周开始应用丝裂霉C20mg加蒸馏水40mL,1次/周,6次后改为每月1次,维持1年。结果所有入选病例均获随访12￣24个月,12个月内肿瘤复发3例,复发后进展2例,38例随访24个月无复发。42例中均未见明显药物副作用,仅有4例出现轻微尿道刺激症状。结论丝裂霉素C对浅表性膀胱癌有较明显的治疗和预防复发的作用,灌注后副作用小,患者耐受性好,是较好的预防和治疗浅表膀胱癌的药物。 Objective To evaluate the efficacy and safety of intravesical instillation of mitomycin A small dose to prevent postoperative recurrence of superficial bladder cancer. Methods Forty-two patients with superficial bladder cancer from 1998 to 2004 were treated with intravesical chemotherapy. 32 cases underwent transurethral resection of bladder tumor (TURBt) and 10 cases underwent partial bladder resection. All the selected cases Pathologically confirmed as superficial tumors, 1 week after the start of the application of mitomycin C20mg plus distilled water 40mL, 1 / week, 6 times changed to monthly 1, for 1 year. Results All the selected cases were followed up for 12-24 months. There were 3 cases of tumor recurrence within 12 months, 2 cases after the recurrence, and 38 cases had no recurrence after 24 months of follow-up. 42 cases were no obvious side effects of drugs, only 4 cases of mild urethral irritation. Conclusion Mitomycin C has obvious effect on the treatment and prevention of recurrence of superficial bladder cancer. It has low side effects after perfusion and good patient tolerance. It is a good drug for the prevention and treatment of superficial bladder cancer.